Treatment of severe acute respiratory syndrome

Chest

Volumn 126, Issue 3, 2004, Pages 670-674

  Hui, David S C ^a,b   Sung, Joseph J Y ^a,c  

^a Prince of Wales Hospital ^*

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; ALPHAN3 INTERFERON; ANGIOTENSIN RECEPTOR; CONSENSUS INTERFERON; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCYRRHIZIC ACID; HUMAN MONOCLONAL ANTIBODY; INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON ALPHA; PROTEINASE; RIBAVIRIN; RITONAVIR; SARS CORONAVIRUS ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ADULT RESPIRATORY DISTRESS SYNDROME; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASSISTED VENTILATION; BRADYCARDIA; BRONCHIOLITIS; CHINA; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; ENDOTRACHEAL INTUBATION; GENOME ANALYSIS; HEALTH CARE PERSONNEL; HELPER CELL; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HYPOXEMIA; LUNG INJURY; MORTALITY; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY FAILURE; SARS CORONAVIRUS; SEROLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; SINGAPORE; TAIWAN; VIRUS TRANSMISSION;

EID: 4544300721     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3.670     Document Type: Editorial

References (54)

1. Lee N, Hui DS, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986-1994
2. Twu SJ, Chen TJ, Chen CJ, et al. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 2003; 9:718-720
3. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003; 289:2801-2809
4. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003; 9:713-717
5. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available at: http:/www.who.int/ csr/sars/country/table2003_09_23/en/. Accessed August 9, 2004
6. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362:1353-1358
7. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767-1772
8. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 2003; 58:686-689
9. Tsui PT, Kwok ML, Yuen H, et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis 2003; 9:1064-1069
10. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest 2003; 124:12-15
11. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361:1615-1617
12. Nhong NS, Zeng GQ. Our strategies for fighting severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168:7-9
13. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003; 302:276-278
14. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community acquired pneumonia: a prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160:1585-1591
15. Jolliet P, Abajo B, Pasquina P, et al. Non-invasive pressure support ventilation in severe community acquired pneumonia. Intensive Care Med 2001; 27:812-821
16. Hui DS, Wong PC, Wang C. Severe acute respiratory syndrome: clinical features and diagnosis. Respirology 2003; 8(suppl):S20-S24
17. Somogyi R, Vesely AE, Azami T, et al. Dispersion of respiratory droplets with open vs closed oxygen delivery masks: implications for the transmission of severe acute respiratory syndrome. Chest 2004; 125:1155-1157
18. Ho JC, Ooi GC, Mok TY, et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168:1449-1456
19. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59:414-420
20. Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. Nature 2003; 423:4
21. Cinatl J, Morgenstern, Bauer G, et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003; 361:2045-2046
22. Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis [serial online] April 2004. Available at: http://www.cdc.gov/ncidod/EID/vol10no4/03- 0458.htm. Accessed August 9, 2004
23. Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300:1394-1399
24. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300:1399-1404
25. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3Clpro) structure: basis for design of anti-SARS drugs. Science 2003; 300:1763-1767
26. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252-256
27. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 2003; 9:399-406
28. Hurst M, Faulds D. Lopinavir. Drugs 2000; 60:1371-1381
29. Wong KT, Antonio GE, Hui DS, et al. Thin section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 2003; 228:395-400
30. Epler GR. Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001; 161:158-164
31. Tse GM, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004; 57:260-265
32. Wong CK, Lam CWK, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95-103
33. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361:1773-1778
34. Fisman DN. Hemophagocytic syndrome and infection. Emerg Infect Dis 2000; 6:60-68
35. Lai KN, Leung JC, Metz CN, et al. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol 2003; 199:496-508
36. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003; 9:1381-1387
37. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349:507-508
38. Ahmed R, Biron C. Immunity to viruses. In: Paul WE, ed. Fundamental immunology. Philadelphia, PA: Lippincott-Raven, 1999; 1295
39. Sperber SJ, Hayden FG. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. J Interferon Res 1989; 9:285-293
40. Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet 2003; 362:293-294
41. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290:3222-3228
42. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004; 10:290-293
43. Pearson H, Clarke T, Abbott A, et al. SARS: what have we learned? Nature 2003; 424:121-126
44. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003; 362:1895-1896
45. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454
46. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004; 101:2536-2541
47. Poon LL, Chan KH, Wong OK, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003; 28:233-238
48. Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003; 49:1976-1980
49. Ng EK, Ng PC, Hon KL, et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem 2003; 49:2085-2088
50. Grant PR, Garson JA, Teddar RS, et al. Detection of SARS coronavirus in plasma by real-time RT-PCR. N Engl J Med 2003; 349:2468-2469
51. World Health Organization. Severe acute respiratory syndrome (SARS) in Singapore: update 2. Available at: http://www.who.int/csr/don/2003_09_24/en/. Accessed August 9, 2004
52. World Health Organization. Severe acute respiratory syndrome (SARS) in Taiwan, China. Available at: http://www.who.int/csr/don/2003_12_17/en/. Accessed August 9, 2004
53. Parry J. WHO confirms SARS in Chinese journalist. BMJ 2004; 328:65
54. World Health Organization. New case of laboratory confirmed SARS in Guangdong, China- Update 5. Available at: http://www.who.int/csr/don/2004_01_31/ en/. Accessed August 9, 2004